Skip to main content
Explore URMC
menu

Treating Head and Neck Cancer or Prostate Cancer with Combination Drugs: Avelumab + Bempegaldesleukin

Research Question:
What is the effect of the combination of avelumab + bempegaldesleukin (NKTR-214 ) in locally advanced squamous cell carcinoma of the head and neck (metastatic SCCHN) - and avelumab + bempegaldesleukin (NKTR-214) + talazoparib or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)?

Basic Study Information

Purpose:
This study will test the combination of drugs, avelumab + bempegaldesleukin (NKTR-214 ), in treating locally advanced skin cancer of the head and neck (metastatic squamous cell carcinoma). It will also look at avelumab + bempegaldesleukin (NKTR-214) + either talazoparib or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). Inclusion Criteria: •Participants must be ≥ 18 years old. •Participants with squamous cell carcinoma of the head or neck or mCRPC.

Location: University of Rochester Medical Center
Study Reference #: IHAN19157

Lead Researcher (Principal Investigator)

Lead Researcher:  Ronald Maggiore

Study Contact Information

Study Coordinator: Amy Jasek
Phone: (585) 273-1912
Email: Amy_Jasek@URMC.Rochester.edu

Additional Study Details

Return to Search